Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

3.150 UNCHANGED
Streaming Delayed Price Updated: 11:44 AM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Second Quarter 2024 Financial Results on August 12
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming BTIG Biotech Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22 ↗
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. 
Via Talk Markets
News headline image
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget ↗
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
News headline image
3 Penny Stocks to Buy if You Want to Spend Less and Earn More ↗
These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential. 
Via InvestorPlace
News headline image
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Esperion to Participate in Upcoming June Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study ↗
Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant LDL-C reduction in hypercholesterolemia patients. With no serious adverse... 
Via Benzinga
News headline image
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
Via AB Newswire
News headline image
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars ↗
Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024... 
Via Benzinga
News headline image
Why Is AgriFORCE Growing (AGRI) Stock Down 31% Today? ↗
AgriFORCE Growing stock is falling hard on Tuesday after the company announced an offering for AGRI shares from stockholders. 
Via InvestorPlace
News headline image
Why Is GreenPower Motor (GP) Stock Down 36% Today? ↗
GreenPower Motor stock is down on Tuesday after the EV company priced a public offering for 1.5 million shares of GP stock. 
Via InvestorPlace
News headline image
Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today? ↗
Esperion Therapeutics stock is up on Tuesday with heavy trading of ESPR shares after the company beat EPS and revenue estimates in Q1. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Tuesday! 
Via InvestorPlace
News headline image
Esperion Reports First Quarter 2024 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming May Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.